Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

Can a weight-loss injection truly safeguard your vision? :eyes: A significant study conducted in the US involving more than ...

A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy (GA) patients’ lives. | A new campaign for Astellas ...

Patients with treatment-naive neovascular age-related macular degeneration have positive outcomes with faricimab at 1 year, ...

A new study published in Clinical & Experimental Ophthalmology found that faricimab was effective in treating patients with neovascular age-related macular degeneration (nAMD) who had not previously ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of ...

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...